Levodopa in the treatment of (PRE) senile dementia
Identifieur interne : 001F81 ( Main/Corpus ); précédent : 001F80; suivant : 001F82Levodopa in the treatment of (PRE) senile dementia
Auteurs : K. Jellinger ; H. Flament ; P. Riederer ; H. Schmid ; L. AmbroziSource :
- Mechanisms of Ageing and Development [ 0047-6374 ] ; 1979.
Abstract
A progressive decrease of dopamine and related enzyme activities and a decline in the dopaminergic receptor functions in the striatum and limbic system controlling behavior have been observed in senescent brain. These changes provide a neurochemical basis for some behavioral and mental disturbances of the aged and suggest the possibility of a substitution therapy of neurotransmitter deficiency of senile and presenile dementia. Previous reports on the effects of levodopa treatment of dementia in parkinsonism and aging have given conflicting results. A controlled double-blind study of 6 months' administration of levodopa plus decarboxylase inhibitor given at oral doses of 250 mg daily versus placebo in twelve patients aged 54–60 years showing initial signs of organic dementia was performed. Clinical rating of twelve parameters of organic brain syndrome and psychometric studies using three subtests of the HAWIE (digit span, coding B test and block design) indicate improvement in the overall scores of organic brain syndrome and in particular in the visuospatial functions, visual memory, and visual-motor coordination. In general, improvement increased with the duration of levodopa treatment. These preliminary data suggest some beneficial effect of levodopa treatment in early stages of presenile dementia and thus open new therapeutic aspects in neurogerontology.
Url:
DOI: 10.1016/0047-6374(80)90125-6
Links to Exploration step
ISTEX:CF749ABA44B2E4DCC071EC9F158D64284C184E47Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Levodopa in the treatment of (PRE) senile dementia</title><author><name sortKey="Jellinger, K" sort="Jellinger, K" uniqKey="Jellinger K" first="K." last="Jellinger">K. Jellinger</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</mods:affiliation></affiliation></author><author><name sortKey="Flament, H" sort="Flament, H" uniqKey="Flament H" first="H." last="Flament">H. Flament</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</mods:affiliation></affiliation></author><author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</mods:affiliation></affiliation></author><author><name sortKey="Schmid, H" sort="Schmid, H" uniqKey="Schmid H" first="H." last="Schmid">H. Schmid</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</mods:affiliation></affiliation></author><author><name sortKey="Ambrozi, L" sort="Ambrozi, L" uniqKey="Ambrozi L" first="L." last="Ambrozi">L. Ambrozi</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CF749ABA44B2E4DCC071EC9F158D64284C184E47</idno><date when="1980" year="1980">1980</date><idno type="doi">10.1016/0047-6374(80)90125-6</idno><idno type="url">https://api.istex.fr/document/CF749ABA44B2E4DCC071EC9F158D64284C184E47/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001F81</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Levodopa in the treatment of (PRE) senile dementia</title><author><name sortKey="Jellinger, K" sort="Jellinger, K" uniqKey="Jellinger K" first="K." last="Jellinger">K. Jellinger</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</mods:affiliation></affiliation></author><author><name sortKey="Flament, H" sort="Flament, H" uniqKey="Flament H" first="H." last="Flament">H. Flament</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</mods:affiliation></affiliation></author><author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</mods:affiliation></affiliation></author><author><name sortKey="Schmid, H" sort="Schmid, H" uniqKey="Schmid H" first="H." last="Schmid">H. Schmid</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</mods:affiliation></affiliation></author><author><name sortKey="Ambrozi, L" sort="Ambrozi, L" uniqKey="Ambrozi L" first="L." last="Ambrozi">L. Ambrozi</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Mechanisms of Ageing and Development</title><title level="j" type="abbrev">MAD</title><idno type="ISSN">0047-6374</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1979">1979</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">1–2</biblScope><biblScope unit="page" from="253">253</biblScope><biblScope unit="page" to="264">264</biblScope></imprint><idno type="ISSN">0047-6374</idno></series><idno type="istex">CF749ABA44B2E4DCC071EC9F158D64284C184E47</idno><idno type="DOI">10.1016/0047-6374(80)90125-6</idno><idno type="PII">0047-6374(80)90125-6</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0047-6374</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A progressive decrease of dopamine and related enzyme activities and a decline in the dopaminergic receptor functions in the striatum and limbic system controlling behavior have been observed in senescent brain. These changes provide a neurochemical basis for some behavioral and mental disturbances of the aged and suggest the possibility of a substitution therapy of neurotransmitter deficiency of senile and presenile dementia. Previous reports on the effects of levodopa treatment of dementia in parkinsonism and aging have given conflicting results. A controlled double-blind study of 6 months' administration of levodopa plus decarboxylase inhibitor given at oral doses of 250 mg daily versus placebo in twelve patients aged 54–60 years showing initial signs of organic dementia was performed. Clinical rating of twelve parameters of organic brain syndrome and psychometric studies using three subtests of the HAWIE (digit span, coding B test and block design) indicate improvement in the overall scores of organic brain syndrome and in particular in the visuospatial functions, visual memory, and visual-motor coordination. In general, improvement increased with the duration of levodopa treatment. These preliminary data suggest some beneficial effect of levodopa treatment in early stages of presenile dementia and thus open new therapeutic aspects in neurogerontology.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>K. Jellinger</name><affiliations><json:string>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</json:string></affiliations></json:item><json:item><name>H. Flament</name><affiliations><json:string>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</json:string></affiliations></json:item><json:item><name>P. Riederer</name><affiliations><json:string>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</json:string></affiliations></json:item><json:item><name>H. Schmid</name><affiliations><json:string>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</json:string></affiliations></json:item><json:item><name>L. Ambrozi</name><affiliations><json:string>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</json:string></affiliations></json:item></author><language><json:string>eng</json:string></language><abstract>A progressive decrease of dopamine and related enzyme activities and a decline in the dopaminergic receptor functions in the striatum and limbic system controlling behavior have been observed in senescent brain. These changes provide a neurochemical basis for some behavioral and mental disturbances of the aged and suggest the possibility of a substitution therapy of neurotransmitter deficiency of senile and presenile dementia. Previous reports on the effects of levodopa treatment of dementia in parkinsonism and aging have given conflicting results. A controlled double-blind study of 6 months' administration of levodopa plus decarboxylase inhibitor given at oral doses of 250 mg daily versus placebo in twelve patients aged 54–60 years showing initial signs of organic dementia was performed. Clinical rating of twelve parameters of organic brain syndrome and psychometric studies using three subtests of the HAWIE (digit span, coding B test and block design) indicate improvement in the overall scores of organic brain syndrome and in particular in the visuospatial functions, visual memory, and visual-motor coordination. In general, improvement increased with the duration of levodopa treatment. These preliminary data suggest some beneficial effect of levodopa treatment in early stages of presenile dementia and thus open new therapeutic aspects in neurogerontology.</abstract><qualityIndicators><score>6.476</score><pdfVersion>1.2</pdfVersion><pdfPageSize>468 x 684 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1378</abstractCharCount><pdfWordCount>4088</pdfWordCount><pdfCharCount>27565</pdfCharCount><pdfPageCount>12</pdfPageCount><abstractWordCount>199</abstractWordCount></qualityIndicators><title>Levodopa in the treatment of (PRE) senile dementia</title><pii><json:string>0047-6374(80)90125-6</json:string></pii><genre><json:string>research-article</json:string></genre><serie><pages><last>605</last><first>589</first></pages><genre></genre><language><json:string>unknown</json:string></language><title>Neurobiology of Aging</title></serie><host><volume>14</volume><pii><json:string>S0047-6374(00)X0133-9</json:string></pii><pages><last>264</last><first>253</first></pages><issn><json:string>0047-6374</json:string></issn><issue>1–2</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>Mechanisms of Ageing and Development</title><publicationDate>1980</publicationDate></host><categories><wos><json:string>GERIATRICS & GERONTOLOGY</json:string><json:string>BIOCHEMISTRY & MOLECULAR BIOLOGY</json:string><json:string>CELL BIOLOGY</json:string></wos></categories><publicationDate>1979</publicationDate><copyrightDate>1980</copyrightDate><doi><json:string>10.1016/0047-6374(80)90125-6</json:string></doi><id>CF749ABA44B2E4DCC071EC9F158D64284C184E47</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/CF749ABA44B2E4DCC071EC9F158D64284C184E47/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/CF749ABA44B2E4DCC071EC9F158D64284C184E47/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/CF749ABA44B2E4DCC071EC9F158D64284C184E47/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/CF749ABA44B2E4DCC071EC9F158D64284C184E47/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Levodopa in the treatment of (PRE) senile dementia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1980</date></publicationStmt><notesStmt><note>Paper presented at the Sixth European Symposium on Basic Research in Gerontology, Munich, F.R.G., September 4–7, 1979.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Levodopa in the treatment of (PRE) senile dementia</title><author><persName><forename type="first">K.</forename><surname>Jellinger</surname></persName><note type="correspondence"><p>Correspondence address: Prof. Dr. K. Jellinger, L. Boltzmann Institute of Clinical Neurobiology, Lainz-Hospital, 1, Wolkersbergenstrasse, A 1130 Vienna, Austria.</p></note><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</affiliation></author><author><persName><forename type="first">H.</forename><surname>Flament</surname></persName><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</affiliation></author><author><persName><forename type="first">P.</forename><surname>Riederer</surname></persName><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</affiliation></author><author><persName><forename type="first">H.</forename><surname>Schmid</surname></persName><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</affiliation></author><author><persName><forename type="first">L.</forename><surname>Ambrozi</surname></persName><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</affiliation></author></analytic><monogr><title level="j">Mechanisms of Ageing and Development</title><title level="j" type="abbrev">MAD</title><idno type="pISSN">0047-6374</idno><idno type="PII">S0047-6374(00)X0133-9</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1979"></date><biblScope unit="volume">14</biblScope><biblScope unit="issue">1–2</biblScope><biblScope unit="page" from="253">253</biblScope><biblScope unit="page" to="264">264</biblScope></imprint></monogr><idno type="istex">CF749ABA44B2E4DCC071EC9F158D64284C184E47</idno><idno type="DOI">10.1016/0047-6374(80)90125-6</idno><idno type="PII">0047-6374(80)90125-6</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1980</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>A progressive decrease of dopamine and related enzyme activities and a decline in the dopaminergic receptor functions in the striatum and limbic system controlling behavior have been observed in senescent brain. These changes provide a neurochemical basis for some behavioral and mental disturbances of the aged and suggest the possibility of a substitution therapy of neurotransmitter deficiency of senile and presenile dementia. Previous reports on the effects of levodopa treatment of dementia in parkinsonism and aging have given conflicting results. A controlled double-blind study of 6 months' administration of levodopa plus decarboxylase inhibitor given at oral doses of 250 mg daily versus placebo in twelve patients aged 54–60 years showing initial signs of organic dementia was performed. Clinical rating of twelve parameters of organic brain syndrome and psychometric studies using three subtests of the HAWIE (digit span, coding B test and block design) indicate improvement in the overall scores of organic brain syndrome and in particular in the visuospatial functions, visual memory, and visual-motor coordination. In general, improvement increased with the duration of levodopa treatment. These preliminary data suggest some beneficial effect of levodopa treatment in early stages of presenile dementia and thus open new therapeutic aspects in neurogerontology.</p></abstract></profileDesc><revisionDesc><change when="1979-12-03">Received</change><change when="1979">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>MAD</jid><aid>80901256</aid><ce:pii>0047-6374(80)90125-6</ce:pii><ce:doi>10.1016/0047-6374(80)90125-6</ce:doi><ce:copyright type="unknown" year="1980"></ce:copyright></item-info><head><ce:article-footnote><ce:label>☆</ce:label><ce:note-para>Paper presented at the Sixth European Symposium on Basic Research in Gerontology, Munich, F.R.G., September 4–7, 1979.</ce:note-para></ce:article-footnote><ce:title>Levodopa in the treatment of (PRE) senile dementia</ce:title><ce:author-group><ce:author><ce:given-name>K.</ce:given-name><ce:surname>Jellinger</ce:surname><ce:cross-ref refid="COR1"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>H.</ce:given-name><ce:surname>Flament</ce:surname></ce:author><ce:author><ce:given-name>P.</ce:given-name><ce:surname>Riederer</ce:surname></ce:author><ce:author><ce:given-name>H.</ce:given-name><ce:surname>Schmid</ce:surname></ce:author><ce:author><ce:given-name>L.</ce:given-name><ce:surname>Ambrozi</ce:surname></ce:author><ce:affiliation><ce:textfn>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>†</ce:label><ce:text>Correspondence address: Prof. Dr. K. Jellinger, L. Boltzmann Institute of Clinical Neurobiology, Lainz-Hospital, 1, Wolkersbergenstrasse, A 1130 Vienna, Austria.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="3" month="12" year="1979"></ce:date-received><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>A progressive decrease of dopamine and related enzyme activities and a decline in the dopaminergic receptor functions in the striatum and limbic system controlling behavior have been observed in senescent brain. These changes provide a neurochemical basis for some behavioral and mental disturbances of the aged and suggest the possibility of a substitution therapy of neurotransmitter deficiency of senile and presenile dementia. Previous reports on the effects of levodopa treatment of dementia in parkinsonism and aging have given conflicting results. A controlled double-blind study of 6 months' administration of levodopa plus decarboxylase inhibitor given at oral doses of 250 mg daily versus placebo in twelve patients aged 54–60 years showing initial signs of organic dementia was performed. Clinical rating of twelve parameters of organic brain syndrome and psychometric studies using three subtests of the HAWIE (digit span, coding B test and block design) indicate improvement in the overall scores of organic brain syndrome and in particular in the visuospatial functions, visual memory, and visual-motor coordination. In general, improvement increased with the duration of levodopa treatment. These preliminary data suggest some beneficial effect of levodopa treatment in early stages of presenile dementia and thus open new therapeutic aspects in neurogerontology.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Levodopa in the treatment of (PRE) senile dementia</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Levodopa in the treatment of (PRE) senile dementia</title></titleInfo><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Jellinger</namePart><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</affiliation><description>Correspondence address: Prof. Dr. K. Jellinger, L. Boltzmann Institute of Clinical Neurobiology, Lainz-Hospital, 1, Wolkersbergenstrasse, A 1130 Vienna, Austria.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Flament</namePart><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Riederer</namePart><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Schmid</namePart><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Ambrozi</namePart><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz-Hospital, Vienna Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1979</dateIssued><dateCaptured encoding="w3cdtf">1979-12-03</dateCaptured><copyrightDate encoding="w3cdtf">1980</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">A progressive decrease of dopamine and related enzyme activities and a decline in the dopaminergic receptor functions in the striatum and limbic system controlling behavior have been observed in senescent brain. These changes provide a neurochemical basis for some behavioral and mental disturbances of the aged and suggest the possibility of a substitution therapy of neurotransmitter deficiency of senile and presenile dementia. Previous reports on the effects of levodopa treatment of dementia in parkinsonism and aging have given conflicting results. A controlled double-blind study of 6 months' administration of levodopa plus decarboxylase inhibitor given at oral doses of 250 mg daily versus placebo in twelve patients aged 54–60 years showing initial signs of organic dementia was performed. Clinical rating of twelve parameters of organic brain syndrome and psychometric studies using three subtests of the HAWIE (digit span, coding B test and block design) indicate improvement in the overall scores of organic brain syndrome and in particular in the visuospatial functions, visual memory, and visual-motor coordination. In general, improvement increased with the duration of levodopa treatment. These preliminary data suggest some beneficial effect of levodopa treatment in early stages of presenile dementia and thus open new therapeutic aspects in neurogerontology.</abstract><note>Paper presented at the Sixth European Symposium on Basic Research in Gerontology, Munich, F.R.G., September 4–7, 1979.</note><relatedItem type="host"><titleInfo><title>Mechanisms of Ageing and Development</title></titleInfo><titleInfo type="abbreviated"><title>MAD</title></titleInfo><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">198009</dateIssued></originInfo><identifier type="ISSN">0047-6374</identifier><identifier type="PII">S0047-6374(00)X0133-9</identifier><part><date>198009</date><detail type="volume"><number>14</number><caption>vol.</caption></detail><detail type="issue"><number>1–2</number><caption>no.</caption></detail><extent unit="issue pages"><start>1</start><end>271</end></extent><extent unit="pages"><start>253</start><end>264</end></extent></part></relatedItem><identifier type="istex">CF749ABA44B2E4DCC071EC9F158D64284C184E47</identifier><identifier type="DOI">10.1016/0047-6374(80)90125-6</identifier><identifier type="PII">0047-6374(80)90125-6</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/CF749ABA44B2E4DCC071EC9F158D64284C184E47/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">GERIATRICS & GERONTOLOGY</classCode><classCode scheme="WOS">BIOCHEMISTRY & MOLECULAR BIOLOGY</classCode><classCode scheme="WOS">CELL BIOLOGY</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F81 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001F81 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:CF749ABA44B2E4DCC071EC9F158D64284C184E47
|texte= Levodopa in the treatment of (PRE) senile dementia
}}
| This area was generated with Dilib version V0.6.23. |  |